• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Adenylate kinase 8 (AK8)

ACP13171

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP13171 Target NameAK8
Target SynonymsAK8; C9orf98; Adenylate kinase 8; AK 8; EC 2.7.4.3; EC 2.7.4.6; ATP-AMP transphosphorylase 8FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-479
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ96MA6
Background Information
  • Uniprot Id

    Q96MA6

  • Target Species

    Human

  • Target Name

    AK8

  • Target Full Name

    Adenylate kinase 8

  • Target Function

    Nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. Has highest activity toward AMP, and weaker activity toward dAMP, CMP and dCMP. Also displays broad nucleoside diphosphate kinase activity.

  • Target Subcellular Location

    Cytoplasm, cytosol.

  • Target Protein Families

    Adenylate kinase family

  • Target Synonyms

    AK8; C9orf98; Adenylate kinase 8; AK 8; EC 2.7.4.3; EC 2.7.4.6; ATP-AMP transphosphorylase 8

  • Target Background

    Enables AMP binding activity and nucleobase-containing compound kinase activity. Involved in nucleoside diphosphate phosphorylation and nucleoside triphosphate biosynthetic process. Located in 9+2 motile cilium.

Inquire Recombinant Human Adenylate kinase 8 (AK8) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification